The Curis Lifesciences IPO has opened a fresh conversation in the SME segment this week. With the market already buzzing with multiple offerings, this one has managed to carve out its own space right from Day 1. The company, known for its pharmaceutical manufacturing capabilities, is now looking to raise ₹27.52 crore — and investors are closely tracking every number.
As the subscription window opened on November 7, the early response set the tone for what could be an active few days in the SME IPO landscape.
Market Performance: How Day 1 Looked
The broader market environment stayed firm, and the sentiment spilled over into the IPO space as well. Curis Lifesciences showed movement right from the morning session.
By 11:30 am, the IPO recorded:
- Overall subscription: 1.13 times
- Retail subscription: 0.14 times
- NII subscription: 0.28 times
- QIB subscription: 3.50 times
The numbers reflected steady early participation, especially from institutional investors, which contributed significantly to the initial subscription tally.
Curis Lifesciences IPO – Main News & Key Offer Details
The Curis Lifesciences IPO is a fresh issue of 21,50,000 shares with a price band of ₹120–₹128 per share. The company intends to utilise the proceeds for capital expansion, improving its current manufacturing setup, loan repayment, and meeting working capital needs.
Here’s everything that shapes the IPO:
Curis Lifesciences IPO Important Dates
- Opening Date: November 7
- Closing Date: November 11
IPO Size & Structure
- Total Issue Size: ₹27.52 crore
- Fresh Issue: 21,50,000 equity shares
Price Band
- ₹120–₹128 per equity share
Lot Size
- Minimum and maximum bid for retail investors:
- 2,000 shares
- Investment value: ₹2,56,000
Utilisation of Funds
According to the Red Herring Prospectus, the allocation is planned for:
- Upgradation and enhancement of existing manufacturing facilities
- Construction of a new storage facility
- Repayment of outstanding loans
- Product registrations in other countries
- Working capital requirements
- General corporate purposes
These steps indicate a structured expansion plan aligned with the company's operational roadmap.
Curis Lifesciences IPO Reservation Breakdown
The company has divided the IPO allocation across investor categories:
- QIBs: 10,18,000 shares (47%)
- Retail Investors: 7,16,000 shares (33%)
- NIIs: 3,08,000 shares (14%)
- Market Maker: 1,08,000 shares (5%)
This distribution mirrors typical SME IPO structuring, but the higher QIB allocation has contributed to strong early subscription.
Allotment & Listing Timeline
As per the IPO schedule:
- Allotment Finalisation: Expected on November 12
- Demat Transfer for Successful Bidders: November 13
- Refunds for Non-Allottees: November 13
- Listing Date (NSE SME): November 14 (as per SEBI’s T+3 rule)
These dates ensure a smooth, predictable flow for investors tracking the post-issue process.
Curis Lifesciences – Business Overview
Curis Lifesciences operates in the pharmaceutical manufacturing space, offering a diverse range of products. The company handles multiple formats under regulated processes — a capability that gives it a strong manufacturing base.
Their portfolio includes:
- Tablets
- Capsules
- External preparations
- Oral liquids
- Sterile ophthalmic ointments
The business model is driven by formulation development and consistent capacity utilisation across its product lines.
Financial Performance (As Mentioned in Reference Data)
Curis Lifesciences’ numbers reflect a steady growth trajectory over the last three financial years. Here's the breakup:
Profit After Tax
- FY23: ₹1.88 crore
- FY24: ₹4.87 crore
- FY25: ₹6.11 crore
Revenue From Operations
- FY23: ₹35.45 crore
- FY24: ₹35.56 crore
- FY25: ₹49.13 crore
These figures highlight both stable operations and an upward shift in revenues and profitability, especially in the last reported year.
Summary
The Curis Lifesciences IPO comes at a time when SME offerings are drawing strong investor attention. With a ₹27.52 crore issue size, a structured utilisation plan, and clear financial growth between FY23 and FY25, the company has created momentum from Day 1 of subscription.
Early numbers show active institutional participation and steady retail engagement. The next few days will determine how the subscription builds, but the opening response has already set the narrative.
This IPO story blends market activity, company fundamentals, and a clear timeline — making it one of the closely watched SME IPOs in the market today.
Easy & quick
Leave A Comment?